Altheome is a biomarker and proteomics CRO that accelerates precision medicine research through ultra-sensitive analytical platforms and end-to-end services. The company partners with pharmaceutical, biotech, and academic organizations to develop custom protein biomarker assays, validate candidates, and support clinical trials with high-throughput, multiplexed solutions. Their expertise spans oncology and brain, gut, inflammatory, and cardiovascular health, leveraging technologies like Quanterix SIMOA and MSD electrochemiluminescence.
Funding
Funding not disclosed
Founders
Product
Problem
Biomarker research and drug development programs often face long timelines, high costs, and rigid, one-size-fits-all analytical approaches that fail to meet specific program needs. Standard proteomic platforms frequently lack the sensitivity required to detect low-abundance protein biomarkers, limiting early disease detection and the ability to monitor treatment response effectively.
Solution
Altheome provides end-to-end biomarker and proteomics contract research services, combining ultra-sensitive analytical platforms with deep scientific expertise to accelerate discovery, validation, and clinical translation. The company offers custom assay development, protocol optimization, and high-throughput sample processing across all major biological sample types, supporting programs from early discovery through large-scale commercialization. Their team works as an extension of client laboratories, delivering reliable, actionable biomarker data that supports IND applications and clinical trial decision-making. By bridging discovery and application, Altheome helps partners capture biological signals that standard platforms miss, enabling more informed therapeutic development.
Target Audience
Primary customers are pharmaceutical organizations, biotechnology companies, and academic research institutions that need reliable, ultra-sensitive biomarker analysis for drug development, clinical trials, and translational research programs.
Features
- Ultra-sensitive proteomic biomarker panels utilizing Alamar NULISA, Quanterix SIMOA, and MSD electrochemiluminescence technologies
- Custom biomarker panel design and assay development tailored to specific research objectives
- High-throughput, multiplexed solutions for large-scale clinical sample analysis
- PK/PD studies and adaptive biomarker discovery and validation strategies
- Sample biobanking, logistics, and sequencing services for end-to-end program support
- Specialist expertise in oncology and brain, gut, inflammatory, and cardiovascular health biomarkers
- Data analysis and interpretation services that transform raw results into actionable insights